microRNAs in Cancer: Lessons from Melanoma

Author(s): Eyal Greenberg, Yael Nemlich, Gal Markel

Journal Name: Current Pharmaceutical Design

Volume 20 , Issue 33 , 2014

Become EABM
Become Reviewer
Call for Editor


Melanoma is a high-grade, poorly differentiated malignant tumor of pigment-producing cells (melanocytes), accounting for more than 70% of the skin cancer related deaths. Although new lines of targeted therapy and immunotherapy were introduced lately, durable responses are not common as it is hard to target the elusive metastatic phenotype. microRNAs (miRNAs) are short non-coding RNA molecules that function as specific epigenetic regulators of the transcriptome. miRNAs are involved in a broad spectrum of physiological and pathological processes, including cancer-related functions such as proliferation, cell cycle, migration, invasion, immune evasion and drug resistance. These functions are mostly regulated in melanoma through four molecular deregulated pathways, including the RAS/MAPK pathway, the MITF pathway, the p16INK4A-CDK4-RB pathway and the PI3K-AKT pathway. miRNAs provide a strong platform for delineation of cancer mechanisms. Here we review the diverse roles of miRNAs in melanoma cell biology. Studying miRNA-mediated regulation of aggressive and tumor related features is expected to provide novel mechanistic insights that may pave the way for new diagnostic, prognostic and predictive tools as well as new molecular targets for future therapy.

Keywords: Melanoma, microRNAs, cancer, proliferation, cell cycle, invasion, migration, immune evasion, drug resistance.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 09 September, 2014
Page: [5246 - 5259]
Pages: 14
DOI: 10.2174/1381612820666140128210105
Price: $65

Article Metrics

PDF: 71